A big study tied inflammation to 43% more heart events. The marker was not the CRP on your report.

What the study found. In a paper in the European Journal of Preventive Cardiology, led by Declan O’Regan at Imperial College London, the abstract reports 488,079 UK Biobank participants with blood metabolite profiles and a median follow-up of 15.3 years. People in the highest fifth of GlycA had a hazard ratio of 1.43 (95% CI 1.38 to 1.49) for major cardiovascular events compared with the lowest fifth. The Imperial press release states that as a 43% higher risk of heart attack and stroke. A hazard ratio of 1.43 is a relative figure. Neither the release nor the abstract page gives the absolute rates.

Why this is not a CRP result. GlycA is, in the words of a 2020 review by Ballout and Remaley, the NMR signal from sugar groups attached to circulating plasma proteins. Standard panels do not run it. Your hs-CRP is a separate protein measured by a separate assay. The review puts the correlation between the two at 0.45 to 0.67, which is moderate, and estimates GlycA’s biological variability at about 5% against about 30% for hs-CRP. That second figure is the practical difference: a cold last week can move an hs-CRP, and GlycA moves less.

What happened when hs-CRP was in the model. The abstract reports that GlycA added prognostic information beyond hs-CRP and traditional risk factors, and that the adjusted hazard ratios fell to a range of 1.09 to 1.18 once hs-CRP was accounted for. So most of the 43% overlaps with what hs-CRP already carries, and a smaller part does not. I read the abstract, not the full text, so I cannot say which adjustment produced which end of that range.

What the heart scans showed. In the 70,809 participants with cardiac MRI, the abstract reports that higher GlycA went with smaller left ventricular end-diastolic volume and stroke volume, and a faster heart rate. The press release describes thickened heart walls, smaller chambers and poorer filling. These are cross-sectional associations, so they show what inflammation and heart structure looked like together on one day. They do not show that one caused the other.

What drove GlycA up. The abstract lists trunk fat mass, current smoking, psychological distress and low socioeconomic status as the strongest predictors. The release names the same lifestyle targets: smoking and excess body fat. The authors also suggest that inflammation blood tests combined with genetic risk scores could identify who benefits most from early treatment, and say drugs aimed at interleukin-1 and TNF are in clinical trials for cardiovascular prevention, per News-Medical’s coverage. Those are research directions. They are not something to ask a clinician for.

What the study cannot tell you. The abstract states the design is observational, the cohort is predominantly white, and the mediation analyses cannot establish causality. Nothing in it shows that lowering GlycA lowers risk. The 2020 review adds that GlycA has no established cutoffs and is not in major cardiovascular prevention guidelines, and that NMR analyzer availability limits its use. Labcorp OnDemand sells it inside an expanded heart-health panel, and its own page lists no reference ranges. That is a vendor page, and it is not guidance to buy the test.

What to do with your own report. If it lists hs-CRP, that is the inflammation number with published bands. Our CRP guide uses the AHA/CDC cut points: below 1 mg/L low, 1 to 3 mg/L average, above 3 mg/L high. A high reading during or just after an illness is a reason to repeat it when you are well before drawing a conclusion. A reading that stays high with no infection is a reason to look at the factors the study named, such as smoking and trunk fat, alongside the rest of your lipids and glucose.